Balaji Kalyanaraman
Urology · Florence, KYNPI 1053573659
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,512 of the $7,282 with a category attached, or 62.0%. It is spread thinly across 35 manufacturers, the largest accounting for just 21.2%.
Across 153 payments — averaging $47.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$2K
- Boston Scientific$1K
- Procept Biorobotics Corporation$1K
- Medtronic$467
- Astellas Pharma US Inc$427
- Olympus America Inc.$373
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2,64636%
- Food & beverage$4,51262%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 2 | $1,547 |
| Boston Scientific | 23 | $1,408 |
| Procept Biorobotics Corporation | 12 | $1,326 |
| Medtronic(2 entities) | 11 | $467 |
| Astellas Pharma US Inc | 24 | $427 |
| Olympus America Inc. | 8 | $373 |
| Coloplast | 4 | $175 |
| Teleflex LLC | 3 | $174 |
| Johnson & Johnson | 4 | $148 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $102 |
| AbbVie(2 entities) | 6 | $100 |
| Angiodynamics, Inc. | 2 | $98 |
| Urogen Pharma, Inc. | 3 | $97 |
| Myovant Sciences Inc. | 5 | $96 |
| Antares Pharma, Inc. | 4 | $78 |
| Merck | 4 | $76 |
| Endo Pharmaceuticals Inc. | 4 | $66 |
| Sumitomo Pharma America, Inc. | 4 | $65 |
| Dendreon Pharmaceuticals LLC | 2 | $65 |
| Rochester Medical Corporation | 3 | $45 |
| Endo USA, Inc. | 2 | $44 |
| Laborie Medical Technologies Corp. | 2 | $34 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Amgen | 2 | $30 |
| Civco Medical Instruments | 1 | $29 |
| Axonics, Inc. | 2 | $28 |
| EDAP Technomed Inc | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $17 |
| Dornier Medtech America, Inc | 1 | $17 |
| Blue Earth Diagnostics | 1 | $16 |
| Urovant Sciences Inc | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Smith+Nephew | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,547
- AquaBeam Robotic System$770
- AMS 700$407
- AQUABEAM SYSTEM$377
- iTIND System$298
- GENERAL ERECTILE DYSFUNCTION$148
- UroLift System$136
- AMS$120
- LithoVue$118
- Porges Coloplast$118
- Erleada$113
- LITHOCLAST$105
- INTERSTIM$104
How this compares
$7,282 in reported general payments places this provider in the 75th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 65 | $50,908 |
| Silodosin | 81 | $6,406 |
| Tamsulosin Hcl | 272 | $3,287 |
| Finasteride | 59 | $710 |
| Solifenacin Succinate | 32 | $577 |
| Oxybutynin Chloride ErOxybutynin Chloride | 27 | $568 |
| Tramadol Hcl | 77 | $200 |
| Levofloxacin | 42 | $148 |
| Oxycodone Hcl | 19 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $427 | $50,90865 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 139 urology providers in Kentucky.
Other urology in Florence
- Sonia ChopraFlorence$9K
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.